These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8722418)

  • 1. Higher efficiency of 131I-labeled anti-carcinoembryonic antigen-monoclonal antibody F(ab')2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice.
    Buchegger F; Mach JP; Folli S; Delaloye B; Bischof-Delaloye A; Pèlegrin A
    Recent Results Cancer Res; 1996; 141():19-35. PubMed ID: 8722418
    [No Abstract]   [Full Text] [Related]  

  • 2. Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.
    Buchegger F; Pèlegrin A; Delaloye B; Bischof-Delaloye A; Mach JP
    J Nucl Med; 1990 Jun; 31(6):1035-44. PubMed ID: 2348233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
    Buchegger F; Pfister C; Fournier K; Prevel F; Schreyer M; Carrel S; Mach JP
    J Clin Invest; 1989 May; 83(5):1449-56. PubMed ID: 2708519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F(ab')2 fragments versus intact antibody--an isodose comparison.
    Humm JL; Chin LM; Macklis RM
    J Nucl Med; 1990 Jun; 31(6):1045-7. PubMed ID: 2189961
    [No Abstract]   [Full Text] [Related]  

  • 5. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model.
    Buchegger F; Vacca A; Carrel S; Schreyer M; Mach JP
    Int J Cancer; 1988 Jan; 41(1):127-34. PubMed ID: 3335416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM; Memtsoudis S; Sharkey RM; Blumenthal RD; Dunn RM; Gratz S; Wieland E; Nebendahl K; Schmidberger H; Goldenberg DM; Becker W
    Int J Cancer; 1998 Aug; 77(5):787-95. PubMed ID: 9688314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of radioimmunotherapy using murine monoclonal antibody KIS1 on esophageal squamous cell carcinoma-bearing nude mice.
    Fujii T; Yamana H; Toh Y; Toh U; Fujita H; Shirouzu K; Morimatsu M
    Surg Today; 1997; 27(11):1026-34. PubMed ID: 9413055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
    Pedley RB; Boden JA; Boden R; Dale R; Begent RH
    Br J Cancer; 1993 Jul; 68(1):69-73. PubMed ID: 8318423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations.
    Chalandon Y; Mach JP; Pèlegrin A; Folli S; Buchegger F
    Anticancer Res; 1992; 12(4):1131-9. PubMed ID: 1503403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
    Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
    Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice.
    Buchegger F; Rojas A; Delaloye AB; Vogel CA; Mirimanoff RO; Coucke P; Sun LQ; Raimondi S; Denekamp J; Pèlgrin A
    Cancer Res; 1995 Jan; 55(1):83-9. PubMed ID: 7805046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
    Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of carcinoma of colon with [131I]-labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen.
    Lu QJ; Bian GX; Chen YY; Zhang M; Guo SM; Wen LQ
    Acta Pharmacol Sin; 2005 Oct; 26(10):1259-64. PubMed ID: 16174444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
    Ychou M; Azria D; Menkarios C; Faurous P; Quenet F; Saint-Aubert B; Rouanet P; Pèlegrin M; Bascoul-Mollevi C; Guerreau D; Saccavini JC; Mach JP; Artus JC; Pèlegrin A
    Clin Cancer Res; 2008 Jun; 14(11):3487-93. PubMed ID: 18519781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
    Ychou M; Pelegrin A; Faurous P; Robert B; Saccavini JC; Guerreau D; Rossi JF; Fabbro M; Buchegger F; Mach JP; Artus JC
    Int J Cancer; 1998 Feb; 75(4):615-9. PubMed ID: 9466665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.